Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# Revision of Appendix 3B lodged 16 September 2015 New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \ \ Origin: Appendix 5 \ \ Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 4/03/13$ 

Name of entity				
PARAGON CARE LIMITED				
ABN				
76 o6	4 551 426			
We (	the entity) give ASX the following	g information.		
	1 - All issues ust complete the relevant sections (attack	h sheets if there is not enough space).		
1	*Class of *securities issued or to be issued	Fully paid ordinary shares		
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	1,203,572		
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares to rank equally in all respects with existing ordinary shares.		

<sup>+</sup> See chapter 19 for defined terms.

Fully paid ordinary shares ranking equally Do the \*securities rank equally 4 in all respects with existing ordinary shares. in all respects from the +issue date with an existing +class of quoted +securities? If the additional \*securities do not rank equally, please state: • the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Issue price or consideration \$0.7020 per fully paid ordinary share 5 Purpose of the issue Dividend Reinvestment Plan. 6 (If issued as consideration for the acquisition of assets, clearly identify those assets) 6a Is the entity an +eligible entity Yes that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i The date the security holder 6b 22 November 2017 resolution under rule 7.1A was passed 6c Number of \*securities issued 29,447,189 without security holder approval Refer Annexure 1 Part 1

under rule 7.1

<sup>+</sup> See chapter 19 for defined terms.

6d 16,621,461 new Shares pursuant to the Number of +securities issued with security holder approval Placement under rule 7.1A Refer Annexure 1 Part 2 Nil 6e Number of \*securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) 6f Number of +securities issued 61,435,351 shares issued under the DRP and under an exception in rule 7.2 the entitlement offers concluded on 5 March 2018. Refer Annexure 1 Part 1 Yes. Refer prior Appendix 3B lodged 19 6g If \*securities issued under rule 7.1A, was issue price at least 75% February 2018. of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation. 6h N/A If \*securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to **ASX Market Announcements** 6i Calculate the entity's remaining 4,599,703 Shares remaining issue capacity issue capacity under rule 7.1 and under Rule 7.1 after the Placement rule 7.1A - complete Annexure 1 and release to ASX Market 6,076,467 Shares remaining issue capacity Announcements under Rule 7.1A after the Placement Refer Annexure 1

<sup>+</sup> See chapter 19 for defined terms.

7	<sup>+</sup> Issue dates	12 April 2018			
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.				
	Cross reference: item 33 of Appendix 3B.				
		Number	+Class		
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	273,047,930	Fully paid ordinary shares		
		Number	+Class		
9	Number and +class of all	N/A	N/A		
,	*securities not quoted on ASX (including the *securities in section 2 if applicable)	14/11	14/11		
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	No change to dividend	policy.		
Part	2 - Pro rata issue				
The new shares are not issued pursuant to a Pro Rate Issue and questions 11 to 35 not applicable.					
Part 3 - Quotation of securities You need only complete this section if you are applying for quotation of securities					
34	Type of *securities (tick one)				
(a)	*Securities described in Part 1				
(b)	All other *securities				

<sup>+</sup> See chapter 19 for defined terms.

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

The new shares do not form a new class of securities and questions 35 to 37 not applicable

#### Entities that have ticked box 34(b)

#### Box 34(b) not ticked and questions 38 to 42 not applicable

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  +securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Len Kocovic

Company secretary

Date: 11 April 2018

Appendix 3B Page 6 Doc ID 534155673/v1

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital				
Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	165,018,009			
<ul> <li>Add the following:         <ul> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> </ul> </li> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> </ul>	06-Oct-17 - issue of shares under DRP - 670,677  12-Apr-18 - issue of shares under Dividend Reinvestment Plan (DRP) - 1,203,572  14-Aug-17 - Part consideration for acquisition of Medtek business and earn out consideration in lieu of cash consideration to vendor of Western Biomedical business - 525,920			
Note: Include only ordinary securities here — other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items  Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	Entitlement Offer Shares allotted by 5 March 2018 (ASX waiver of listing rule 7.1) - 59,561,102  Nil			
"A"	226,979,280			

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"				
"B"	0.15 [Note: this value cannot be changed]			
<i>Multiply</i> "A" by 0.15	34,046,892			
Step 3: Calculate "C", the amount of placement capacity under rule 7. that has already been used				
Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:	Anaequip part consideration – 550,898  Surgical Specialties part consideration - 8,823,338			
<ul> <li>Under an exception in rule 7.2</li> </ul>	Institutional placement - 20,072,953			
Under rule 7.1A				
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>				
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>				
"C"	29,447,189			
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	B"] to calculate remaining			
"A" x 0.15	34,046,892			
Note: number must be same as shown in Step 2				
Subtract "C"	29,447,189			
Note: number must be same as shown in Step 3				
<b>Total</b> ["A" x 0.15] – "C"	4,599,703			
	[Note: this is the remaining placement capacity under rule 7.1]			

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities				
Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
"A"  Note: number must be same as shown in Step 1 of Part 1  Step 2: Calculate 10% of "A"	226,979,280			
"D"	0.10  Note: this value cannot be changed			
<b>Multiply</b> "A" by 0.10	22,697,928			
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used				
<ul> <li>Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</li> <li>Notes:         <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	16,621,461 - Institutional Placement			
"E"	16,621,461			

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	22,697,928	
Note: number must be same as shown in Step 2		
Subtract "E"	16,621,461	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	6,076,467	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.